Triple threat: new combo therapy targets Hard-to-Treat cancers
NCT ID NCT06760481
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 25 times
Summary
This early-phase trial tests a combination of two immunotherapy drugs (tiragolumab and atezolizumab) plus a special type of radiation (RadScopal) in people with advanced solid tumors that have not responded to standard treatments. The study aims to see if this triple therapy is safe and shows signs of shrinking tumors. Only 7 participants were enrolled, so results are very preliminary.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The University of Texas M. D. Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.